Horizon Pharma Inc (NASDAQ:HZNP) was rising 18.82% to $10.10 in afternoon trading on Wednesday after the pharmaceutical company announced its preliminary results for the fourth quarter and fiscal year 2013. Horizon Pharma Inc (NASDAQ:HZNP) stock opened at $8.85 in last session, and closed at $10.05, while the day range of stock is $8.48 – $10.52. The stock showed a positive weekly performance of 19.93%.
Shares of Natus Medical Inc (NASDAQ:BABY) a provider of neurodiagnostic and newborn health-care products, popped by as much as 12% after reporting its fourth-quarter results before the opening bell. Natus Medical Inc (NASDAQ:BABY) stock opened at $25.82, in last session and closed at $25.85, by gaining 7.31%. The 52 week range of the stock is $11.40 – $26.87. Company’s market capitalization is $800.41 million.
Medivation Inc (NASDAQ:MDVN) and partner Astellas Pharma Inc. (ALPMY) continue to come out with positive data on their prostate cancer therapy, Xtandi (enzalutamide). The companies presented final results from the phase III randomized, double-blind, placebo-controlled, multi-national PREVAIL study which was conducted in chemo-naïve metastatic prostate cancer patients who had failed androgen deprivation therapy and had few or no symptoms. Medivation Inc (NASDAQ:MDVN) stock decreased/advanced 11.23% and finished the last session at $84.29. The EPS of the stock remained -1.02. Company’s market capitalization is $6.36 billion.
Aratana Therapeutics Inc (NASDAQ:PETX) received encouraging news as its canine-specific monoclonal antibody, AT-005, gained conditional approval from the United States Department of Agriculture (USDA), to aid the treatment of T-cell lymphoma in dogs. Aratana shares rose on the news. Aratana Therapeutics Inc (NASDAQ:PETX) stock opened the session at $19.15, and closed the session at $19.75. The 52 week range of the stock remained $6.56 – $29.32 and the day range was $19.15 – $19.97.